Disease activity after discontinuation of disease-modifying therapies in patients with multiple sclerosis in Argentina: data from the nationwide registry RelevarEM
暂无分享,去创建一个
J. Correale | E. Cristiano | O. Garcea | L. Patrucco | M. Gaitán | B. Silva | R. Alonso | M. Marrodan | M. Alonso Serena | Jimena Míguez | C. Adriana | A. Pappolla | L. Luciana | Cohen Leila | Vrech Carlos | S. Emanuel | Barboza Andres | Deri Norma | Tkachuk Verónica | Zanga Gisela | Tavolini Dario | L. Geraldine | S. Judith | Hryb Javier | Alves Pinheiro Amelia | R. Luciano | Portinari Carla | Barber Josefina | Ibañez Tomas | Brolese Lucia | Ysrraelit Celica | Burgos Marcos | C. Anibal | Knorre Eduardo | Nofal Pedro | L. Felisa | Lopez A Pablo | Liwacki Susana | Blaya Patricio | Piedrabuena Raul | M. Alejandra | Balbuena María Eugenia | Carnero Contentti Edgar | Mainella Carolina | Coppola Mariano | Kohler Matias | Kohler Eduardo | Curbelo María Celeste | Menichini Maria Laura | Tizio Santiago | C. Mariela | Pagani Cassará Fatima | Rojas Juan Ignacio | Sorbara Marcos
[1] L. Massacesi,et al. Sustained disease remission after discontinuation of disease modifying treatments in relapsing-remitting multiple sclerosis. , 2020, Multiple sclerosis and related disorders.
[2] F. Leutmezer,et al. Should I stop or should I go on? Disease modifying therapy after the first clinical episode of multiple sclerosis , 2020, Journal of Neurology.
[3] H. Weiner,et al. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes. , 2019, Multiple sclerosis and related disorders.
[4] J. Correale,et al. The Argentinean multiple sclerosis registry (RelevarEM): Methodological aspects and directions. , 2019, Multiple sclerosis and related disorders.
[5] Devon S. Conway,et al. Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60 , 2019, Multiple sclerosis.
[6] X. Montalban,et al. Multiple sclerosis: clinical aspects , 2018, Current opinion in neurology.
[7] R. Marrie,et al. Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis , 2018, Neurology.
[8] David H. Miller,et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria , 2017, The Lancet Neurology.
[9] R. Berkovich. Clinical and MRI outcomes after stopping or switching disease-modifying therapy in stable MS patients: a case series report. , 2017, Multiple sclerosis and related disorders.
[10] M. Reindl,et al. Discontinuation of disease-modifying therapies in multiple sclerosis – Clinical outcome and prognostic factors , 2017, Multiple sclerosis.
[11] G. Birnbaum. Stopping Disease-Modifying Therapy in Nonrelapsing Multiple Sclerosis: Experience from a Clinical Practice. , 2017, International journal of MS care.
[12] G. Edan,et al. Can we stop immunomodulatory treatments in secondary progressive multiple sclerosis? , 2017, European journal of neurology.
[13] F. Barkhof,et al. The 11-year long-term follow-up study from the randomized BENEFIT CIS trial , 2016, Neurology.
[14] J. Lechner-Scott,et al. Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study , 2016, Journal of Neurology, Neurosurgery & Psychiatry.
[15] B. Weinshenker,et al. Stopping immunomodulatory medications in MS: Frequency, reasons and consequences. , 2015, Multiple sclerosis and related disorders.
[16] Jeffrey A. Cohen,et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. , 2014, Neurology.
[17] J. Aarseth,et al. Stoppers and non‐starters of disease‐modifying treatment in multiple sclerosis , 2013, Acta neurologica Scandinavica.
[18] Y. Ben-Shlomo,et al. Long-term outcome of paediatric-onset multiple sclerosis: a population-based study , 2012, Journal of Neurology, Neurosurgery & Psychiatry.
[19] H. Tremlett,et al. Long-term persistence with the immunomodulatory drugs for multiple sclerosis: a retrospective database study. , 2012, Clinical therapeutics.
[20] M. Konarska,et al. Discontinuation of interferon beta therapy in multiple sclerosis patients with high pre-treatment disease activity leads to prompt return to previous disease activity , 2011, Journal of the Neurological Sciences.
[21] Yinshan Zhao,et al. Relapses in multiple sclerosis are age- and time-dependent , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.
[22] Ludwig Kappos,et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.
[23] M. Trojano,et al. Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosis , 2005, Journal of the Neurological Sciences.
[24] I. Elovaara,et al. Increased disability and MRI lesions after discontinuation of IFN‐β‐1a in secondary progressive MS , 2005, Acta neurologica Scandinavica.
[25] X. Montalban,et al. Interferon beta in relapsing–remitting multiple sclerosis , 2005, Journal of Neurology.
[26] D. Goodkin,et al. Side effect profile and adherence to in the treatment of Multiple Sclerosis with interferon beta-la , 1998, Multiple sclerosis.
[27] Ludwig Kappos,et al. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis , 1998, The Lancet.
[28] S. Vermund,et al. Estimating population prevalence of human immunodeficiency virus infection in urban areas with high rates of intravenous drug use: a model of the Bronx in 1988. , 1989, American journal of epidemiology.
[29] D. Silberberg,et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.